- 21st.BIO has earned a self-affirmed GRAS status for its
animal-free beta-lactoglobulin ingredient, which customers can
now launch in the United States
market.
- 21st.BIO is helping customers bring products to market at an
unprecedented pace, from initiation of development to market
approval in under two years.
- 21st.BIO offers the leading production technology for BLG,
based on precision fermentation technology that has been perfected
over decades and partly licensed from Novonesis (formerly
Novozymes).
- By studying the variation in cows' milk protein, 21st.BIO's
world class scientists have been able to reproduce a highly
nutritious recombinant BLG, which is the most potent bovine whey
protein and has superior nutrition and functionalities. This is why
21st.BIO has named its protein BLG Essential+™.
COPENHAGEN, Denmark and
DAVIS, Calif., Sept. 4, 2024 /PRNewswire/ -- Precision
fermentation platform provider 21st.BIO has earned a self-affirmed
GRAS status for its animal-free beta-lactoglobulin ingredient,
BLG Essential+™, which means customers can now launch in
the United States market.
This breakthrough comes less than two years after 21st.BIO
initiated its development of a strain and production process for
its beta-lactoglobulin protein, BLG Essential+™,
demonstrating the power of the Company's approach, unique expertise
and differentiated precision fermentation platform.
Beta-lactoglobulin is a potent and highly nutritious dairy
protein
The predominant protein in bovine whey, beta-lactoglobulin (BLG)
has attracted considerable food-producer interest for its
high-quality nutrition and advantageous properties in food product
formulation.
Its nutritional profile is impressive, boasting a larger amount
of essential and branched-chain amino acids than whey. For
example:
- BLG contains 45% more leucine than commercially
available whey protein isolates, which is particularly important
for muscle synthesis.
- BLG is tasteless, stable across a wide pH range and can
tolerate heat, making it the ideal ingredient for versatile product
formulations, from clear protein drinks to alternative dairy or
bakery products.
21st.BIO expects its customers' own production of
beta-lactoglobulin to be incorporated into the formulation of foods
such as baked goods and alternative dairy products, as well as
nutritional products for active or sports nutrition, weight
management, and clinical and elderly nutrition.
Unique business model: One market approval for several dairy
protein suppliers
Companies engaged in 21st.BIO's unique development program can
now commercialize their own production of BLG Essential+™ in
the U.S. market. Through 21st.BIO's BLG program, customers gain
access to the world's most advanced production strains and
precision fermentation processes - and optimizations over time.
Furthermore, 21st.BIO is supporting customers in upscaling their
production all the way to full-scale ingredient production. The
Company's diverse global customer base spans food-tech start-ups to
large food ingredients manufacturers. BLG Essential+™ is the
first food protein out of a portfolio of protein ingredients that
21st.BIO will take to the market via this model.
21st.BIO gets solutions to market at an unprecedented
pace
With a strong track record and productive microorganisms
licensed from Novonesis (formerly Novozymes), 21st.BIO is bringing
solutions to market at an unprecedented pace, enabling customers to
bypass years of development and market approval for direct entry
into the U.S. market and empowering customers to produce any food,
materials, agriculture, or biopharma-related protein or peptide of
interest, and scale production to industrial levels to ensure
large-scale availability and cost-effectiveness. Customers in
21st.BIO's development programs benefit from continuous
optimizations of strain and process for improved commercial
attractiveness.
Comprehensive support every step of the way to get products
to market
"We bring our customers access to technology and skills they
could not get anywhere else," said 21st.BIO co-founder and CSO Per
Falholt.
And 21st.BIO co-founder and CEO Thomas
G. Schmidt continues: "We're not just a technology provider
- we're a partner to our customers' on their product journey,
ensuring their success from development to full-scale
manufacturing. We make products, not projects. Our ambition is to
empower our customers to focus more on application, business
development, low-cost production and innovation. And this shows all
the way through our business model, which is designed such that our
success at 21st.BIO depends on our customers' success in the market
with a product; not just on project completion."
21st.BIO derisks product development and supports customers from
strain development, fermentation processes, purification protocols,
pilot production and upscaling guidance, to the regulatory
approvals for market entry. 21st.BIO is working on additional
proteins, including proteins for both foods, materials, agriculture
and beyond.
NOTES TO EDITORS
About 21st.BIO
21st.BIO was founded with one simple mission: to make leading
industrial scale precision fermentation technology accessible to as
many as possible, so companies can successfully take biotech
innovations to market at a competitive price. 21st.BIO's founders
saw that too often, great bio innovation and molecules fail to
translate into commercial success. The innovation is ready, the
market is there, but production costs remain too high for the
product to go mainstream. Industry insiders call it the `valley of
death', and that's exactly what 21st.BIO intends to
bridge.
Founded in 2020, 21st.BIO is headquartered in Copenhagen, Denmark, and has a world-class
R&D team as well as laboratories in both Copenhagen, Denmark and Davis, California. On a mission to support bio
industrial companies globally in upscaling from molecule innovation
to large-scale production, 21st.BIO enables its customers to meet
market demands, and thereby advance the green transition globally.
21st.BIO focuses on developing industrial production technology for
proteins and other molecules of interest for food, materials, and
agricultural industries. Established as a fully integrated
end-to-end partner, 21st.BIO supports its customers from technical
assessment, strain development and optimization, production
processes and upscaling, tech transfer to large scale manufacturing
and regulatory services.
21st.BIO's fermentation technology is in part licensed from
Novonesis, who have developed and perfected their platform over
several decades. Novonesis is a global leader in enzymes,
functional proteins and microorganisms for high value products in
food, household care, and agriculture.
Press contact:
Mathilde Pinon
Marketing & Business Development Manager
m.pinon@21st.bio
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/21st-bio/r/21st-bio-obtains-self-affirmed-gras-status-for-its-precision-fermented-beta-lactoglobulin--21st-bio-,c4032851
The following files are available for download:
https://mb.cision.com/Main/22992/4032851/2980200.pdf
|
Press release
(PDF)
|
https://news.cision.com/21st-bio/i/21st-bio-pilot-plant-facility,c3330348
|
21st BIO pilot plant
facility
|
https://news.cision.com/21st-bio/i/21st-bio-strain-engineering,c3330346
|
21st BIO strain
engineering
|
https://news.cision.com/21st-bio/i/21st-bio-fermentation,c3330347
|
21st BIO
fermentation
|
https://news.cision.com/21st-bio/i/21st-bio-co-founders,c3330349
|
21st BIO
co-founders
|
https://news.cision.com/21st-bio/i/per-falholt-co-founder-and-cso-21st-bio,c3330350
|
Per Falholt co-founder
and CSO 21st BIO
|
https://news.cision.com/21st-bio/i/thomas-schmidt-co-founder-and-ceo-21st-bio,c3330351
|
Thomas Schmidt
co-founder and CEO 21st BIO
|
https://news.cision.com/21st-bio/i/21st-bio-hq-in-copenhagen,c3330353
|
21st BIO HQ in
Copenhagen
|
https://news.cision.com/21st-bio/i/21st-logo-dot-pink,c3330352
|
21st logo dot
pink
|
View original
content:https://www.prnewswire.co.uk/news-releases/21stbio-obtains-self-affirmed-gras-status-for-its-precision-fermented-beta-lactoglobulin-21stbio-customers-can-now-enter-the-us-market-with-their-own-production-using-21stbio-technology-302237720.html